Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Eleven Biotherapeutics, Inc. (NASDAQ: EBIO).

Full DD Report for EBIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: EBIO)

Midday Gainers / Losers (05/16/2018)
Gainers: IHT +50% . BLNK +36% . EBIO +21% . GEMP +18% . VNET +18% . FSI +16% . ABAX +16% . BBOX +13% . ASNA +14% . NSPR +14% . More news on: Innsuites Hospitality Trust, Blink Charging Co., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ....
Source: SeekingAlpha
Date: May, 16 2018 13:00
Eleven Biotherapeutics changes its name to Sesen Bio
Eleven Biotherapeutics (NASDAQ: EBIO ) announces its name change to Sesen Bio, Inc. Sesen Bio will trade under the new symbol “SESN,” effective on May 17. More news on: Eleven Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 16 2018 07:59
Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
Name Change Reflects Company’s Focus on Late-Stage Oncology Drug Development Appointments of Senior Medical Advisor and Vice President of Regulatory Affairs Strengthen Leadership Team as Company Prepares for Phase 3 Three-month NMIBC Data Eleven Biotherapeutics, Inc. (Nasd...
Source: Business Wire
Date: May, 16 2018 06:30
After Hours Gainers / Losers (05/15/2018)
Top gainers:   BOOT   +8.4% .  ACRX +3.6% . EBIO   +3.4% . PETQ +3.1% . SUPV   +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 17:35
Eleven Biotherapeutics beats by $0.02
Eleven Biotherapeutics (NASDAQ: EBIO ): Q1 EPS of -$0.11 beats by $0.02 . Cash and equivalents of $19.7M Shares +3.4% . Press Release More news on: Eleven Biotherapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 15 2018 16:46
Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
Company to Host Conference Call in Conjunction with AUA Presentation on May 21, 2018 Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today reported pipeline updates...
Source: Business Wire
Date: May, 15 2018 16:05
Keeping It Simple On The Short Side
Welcome to Editor's Notes! I aim to sort through the ideas we publish each day and highlight a few that may be of interest to readers, along with comments that may add a helpful gloss. If you have thoughts, comment below or send me a direct message and let me know what you think. Your fe...
Source: SeekingAlpha
Date: May, 11 2018 13:20
ImmunoGen: An Extremely Promising ADC Therapeutic Innovator
Choose clients as you would friends. - Charlie Munger ImmunoGen (NASDAQ: IMGN ) is a highly promising bioscience that is harnessing the power of ADC to deliver the next-generation cancer treatment. The company has an invaluable asset, ADC that, in and of itself, is licensed to other st...
Source: SeekingAlpha
Date: May, 09 2018 02:02
After Hours Gainers / Losers (05/04/2018)
Top gainers:   ALSN   +4.8% .  AAON +1.9% . HEAR   +1.9% . AGX +1.7% . CZR   +1.7% . More news on: Allison Transmission, AAON, Inc., Turtle Beach Corporation, Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 17:35
Rounds Report: Eleven Train Heads Further North While Achaogen Gained Mixed ADCOM Results
You must value the business in order for you to value the stock. - Charlie Munger Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 02, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and inte...
Source: SeekingAlpha
Date: May, 04 2018 03:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-162.743.263.442.7314,970,574
2018-05-152.762.692.782.672,312,453
2018-05-142.882.812.892.662,756,359
2018-05-112.672.782.822.56013,523,111
2018-05-102.902.653.002.654,824,482

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-163,499,2897,955,90443.9835Short
2018-05-15758,4131,310,48757.8726Short
2018-05-14922,1021,484,30962.1233Short
2018-05-111,095,1051,849,39059.2144Short
2018-05-101,602,0102,570,74862.3169Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EBIO.


About Eleven Biotherapeutics, Inc. (NASDAQ: EBIO)

Logo for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EBIO)

      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: May, 16 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: May, 16 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 04 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
      Filing Type: DFiling Source: edgar
      Filing Date: April, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 05 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 04 2018

       

       


      Daily Technical Chart for (NASDAQ: EBIO)

      Daily Technical Chart for (NASDAQ: EBIO)


      Stay tuned for daily updates and more on (NASDAQ: EBIO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EBIO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of EBIO and does not buy, sell, or trade any shares of EBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/